1Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar, Haryana, India
2MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, India
3Delhi Pharmaceutical Sciences and Research University, New Delhi, Delhi, India
*Corresponding Author E-mail: tanujhooda2010@gmail.com
Glimepiride and Gliclazide are classified as Biopharmaceutical Classification System (BCS) Class II drugs, characterized by low aqueous solubility.
This study aims to evaluate the In Vivo pharmacokinetics of Glimepiride nanosuspension (GLMP-NS) and Gliclazide nanosuspension (GLC-NS), both prepared using the precipitation–ultrasonication method.
The antidiabetic efficacy of GLMP-NS and GLC-NS was assessed in streptozotocin-induced diabetic rats and compared with that of pure Glimepiride (GLMP) and Gliclazide (GLC), respectively, using appropriate analytical techniques.
The results demonstrated that the reduced particle size and enhanced entrapment efficiency of GLMP-NS and GLC-NS significantly improved the In Vivo bioavailability of their respective drugs. Both nanosuspensions led to a more rapid and pronounced reduction in blood glucose levels in diabetic rats. Furthermore, pharmacokinetic analysis revealed a 2.9-fold and 7.36-fold increase in the oral bioavailability of Glimepiride and Gliclazide, respectively, when administered as nanosuspensions.
This study highlights a significant improvement in the dissolution and bioavailability of pure Glimepiride and Gliclazide when formulated as nanosuspensions, demonstrating their potential for enhanced therapeutic efficacy.
Glimepiride, Gliclazide, Nanosuspensions, Bioavailability, In Vivo studies
